Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer

• Status: Recruiting
• Trial end date: 2023-10-31
• Target enrollment: 0
• Participant gender: Female

Summary

Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxane Chemotherapy in Breast Cancer

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of Qinghai University

Criteria

Inclusion Criteria:

1. The patient was at least 18 years old and had reported grade 1 or higher neuropathic symptoms for more than 2 weeks;

2. Patients were screened for eligibility by the investigator prior to enrollment, including verification of baseline neuropathic symptoms.

3. Patients had a diagnosis of stage I, II, or IIIA breast cancer;

4. Have completed at least 2 weeks of chemotherapy;

5. Higher scores indicate more severe symptoms;

6. Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent);

7. Eastern Cooperative Oncology Group (ECOG ) score of physical condition (0-1);

8. Patients with previous local recurrence were eligible;

9. The basic indexes were consistent, and the blood routine and ECG were normal.

Exclusion Criteria:

1. patients with needle phobia;

2. Low platelet count (<50 000); co-morbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels <10 g/dl and haematocrit <30; anaemia on active pharmacological treatment or receiving blood transfusion or steroids;

3. having metastatic or recurrent disease, history of preexisting peripheral neuropa- thy prior to chemotherapy, uncontrolled seizure disorder, unstable cardiac disease or myocardial infarction within 6 months prior to study entry;

4. Being pregnant or nursing, or having used acupuncture for peripheral neuropathy within 6 months prior to study entry;

5. Life expectancy <6 months;

6. Lymphedema of limbs;